We are monitoring the impact of COVID-19 & Recession alarm on North America Antinuclear Antibody Test Market Get in touch with us for detailed analysis Know More
Share on

North America Antinuclear Antibody Test Market Research Report - Segmented By Disease, Technique, Product, End User & Country (U.S, Canada & Rest of North America) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2022 to 2027)

Published: January, 2022
ID: 3170
Pages: 145

North America Antinuclear Antibody Test Market Size & Growth (2022 to 2027):

As per the research report, the size of the North America Antinuclear Antibody Test Market is valued at USD 443.19 million in 2022 and expected to reach USD 784.54 million by 2027 at a CAGR of 12.10% during the forecast period 2022 to 2027.

Increased frequency of autoimmune disorders such as rheumatoid arthritis and SLE and public awareness of these diseases are driving the antinuclear antibody test market in North America.

Autoimmune diseases can result in type 1 diabetes. As a result, the number of persons with diabetes increased from 108 million to 422 million between 1980 and 2014, according to the WHO. Other drivers propelling the market in North America include an increase in people's healthcare spending as a result of developing economies and government healthcare insurance and reimbursement laws.

Antinuclear antibody testing is becoming more popular for SLE and other autoimmune diseases, and it is expected to grow in the future. The function of the primary healthcare physician's delivery system is to boost the need for ANA. Autoimmune illnesses such as lupus erythematosus and rheumatoid arthritis are becoming more common, driving increased market demand. Government initiatives for early diagnosis and increased research and development activities in autoimmune illnesses are also likely to boost market demand. The ANA tests are pretty precise. As a result, it contributes to the growth of the antinuclear antibody test market in North America. 

Factors like this contribute to the North America Antinuclear Antibody Test market during the forecasted period.

Diagnostic errors, product approval issues, and a scarcity of trained labor impede the antinuclear antibody test market's growth in North America.

Furthermore, the cost of these tests is less prohibitively expensive for patients, which could limit sales in the North American market. The market growth is hampered by a lack of experienced labor, product approval, and diagnostics flaws.

Due to a lack of test consistency and variations in solid-phase preparation, clinical performance is very variable. In addition, the specificity and overall accuracy of tests can also be low due to the engineering of these methods to achieve high clinical sensitivity.

This research report on the North America Antinuclear Antibody Test Market has been segmented and sub-segmented into the following categories.

By Disease: 

  • SLE
  • Rheumatoid Arthritis

By Technique:

  • Immunofluorescence
  • Multiplex
  • ELISA

By Product:

  • Software
  • Systems
  • Services
  • Reagents
  • Assay Kits

By End User:

  • Hospitals
  • Clinical Labs

By Country:

  • U.S
  • Canada
  • Rest of North America

Geographically, North America is expected to lead the ANA market during the forecast period. An aging population that is more prone to illnesses with a deteriorating immune system contributes to the region's dominance. This results in a greater need for early diagnosis and effective treatment. 

The Centres for Disease Control and Prevention (CDC) report that GBS can affect people. However, it is becoming increasingly common in seniors, resulting in increased demand due to the country's aging population. Factors like this are driving the market in North America during the forecasted period.

During the estimated period, the United States Antinuclear Antibody Test Market is expected to dominate the North American market for Antinuclear Antibody Tests. According to a report published by the Foundation for Peripheral Neuropathy, Guillain-Barre Syndrome (GBS) impacted 3,000-6,000 people in the United States each year in 2019. The number of people insured by medical insurance in the United States is also increasing, propelling the industry in this region. The presence of prominent companies in the United States, such as Alere Inc., Antibodies Inc., Bio-Rad Laboratories, and others, is likely to fuel market growth, providing a significant revenue share and boosting the ANA market's revenue throughout the forecast period.

The Canada Antinuclear Antibody Test Market is predicted to reach a decent CAGR during the forecasted period.

KEY MARKET PLAYERS

Companies playing a dominant role in the North America Antinuclear Antibody Test Market profiled in this report are Zeus Scientific Inc., Inova Diagnostics, Immuno Concepts, Euroimmun AG, Antibodies Inc., Thermo Fisher Scientific inc., Trinity Biotech plc, ERBA Diagnostics Inc., Bio-Rad Laboratories Inc., and Alere Inc.,

1.Introduction          

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods  

                1.4 General Study Assumptions                

2. Research Methodology                   

                2.1 Introduction       

                2.2 Research Phases                      

        2.2.1 Secondary Research           

        2.2.2 Primary Research 

        2.2.3 Econometric Modelling      

        2.2.4 Expert Validation  

                2.3 Analysis Design 

                2.4 Study Timeline  

3. Overview               

                3.1 Executive Summary                

                3.2 Key Inferences 

                3.3 Epidemology      

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)            

                4.1 Market Drivers  

                4.2 Market Restraints                    

                4.3 Key Challenges 

                4.4 Current Opportunities in the Market      

5. Market Segmentation                      

                5.1 Disease

        5.1.1 Introduction           

        5.1.2 SLE              

        5.1.3 Rheumatoid Arthritis          

        5.1.4  Y-o-Y Growth Analysis, By Disease               

        5.1.5  Market Attractiveness Analysis, By Disease             

        5.1.6  Market Share Analysis, By Disease              

                5.2 Technique                   

        5.2.1 Introduction           

        5.2.2 Immunofluorescence         

        5.2.3 Multiplex 

        5.2.4 ELISA         

        5.2.5 Y-o-Y Growth Analysis, By Technique          

        5.2.6 Market Attractiveness Analysis, By Technique        

        5.2.7 Market Share Analysis, By Technique          

                5.3 Product

        5.3.1 Introduction           

        5.3.2 Software  

        5.3.3 Systems   

        5.3.4 Services    

        5.3.5 Reagents & Assay Kits        

        5.3.6 Y-o-Y Growth Analysis, By Product               

        5.3.7  Market Attractiveness Analysis, By Product            

        5.3.8  Market Share Analysis, By Product              

                5.4 End-User                     

        5.4.1 Introduction           

        5.4.2 Hospitals  

        5.4.3 Clinical Labs             

        5.4.4 Y-o-Y Growth Analysis, By End-User            

        5.4.5  Market Attractiveness Analysis, By End-User         

        5.4.6  Market Share Analysis, By End-User           

6. Geographical Analysis                      

                6.1 Introduction       

        6.1.1 Regional Trends    

        6.1.2 Impact Analysis     

        6.1.3 Y-o-Y Growth Analysis        

                        6.1.3.1 By Geographical Area

                        6.1.3.2 By Disease

                        6.1.3.3 By Technique

                        6.1.3.4 By Product

                        6.1.3.5 By End-User

        6.1.4  Market Attractiveness Analysis     

                        6.1.4.1 By Geographical Area

                        6.1.4.2 By Disease

                        6.1.4.3 By Technique

                        6.1.4.4 By Product

                        6.1.4.5 By End-User

        6.1.5  Market Share Analysis      

                        6.1.5.1 By Geographical Area

                        6.1.5.2 By Disease

                        6.1.5.3 By Technique

                        6.1.5.4 By Product

                        6.1.5.5 By End-User

                6.2 United States    

                6.3 Canada

7.Strategic Analysis                

                7.1 PESTLE analysis 

        7.1.1 Political     

        7.1.2 Economic 

        7.1.3 Social         

        7.1.4 Technological         

        7.1.5 Legal          

        7.1.6 Environmental       

                7.2 Porter’s Five analysis      

        7.2.1 Bargaining Power of Suppliers        

        7.2.2 Bargaining Power of Consumers    

        7.2.3 Threat of New Entrants     

        7.2.4 Threat of Substitute Products and Services              

        7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                 

                8.1 Zeus Scientific Inc.                   

        8.1.1 Overview 

        8.1.2 Product Analysis   

        8.1.3 Financial analysis  

        8.1.4 Recent Developments       

        8.1.5 SWOT analysis       

        8.1.6 Analyst View          

                8.2 Inova Diagnostics                     

                8.3 Immuno Concepts                   

                8.4 Euroimmun AG 

                8.5 Antibodies Inc.  

                8.6 Thermo Fisher Scientific Inc.       

                8.7 Trinity Biotech plc                    

                8.8 ERBA Diagnostics Inc.     

                8.9 Bio-Rad Laboratories Inc.                      

                8.10 Alere Inc.                  

9.Competitive Landscape                    

                9.1 Market share analysis    

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures 

                9.4 New Product Launches 

10.Market Outlook and Investment Opportunities                  

Appendix                   

                a) List of Tables                

                b) List of Figures      

  1. North America Antinuclear Antibody Testing Market By Disease, From 2022 to 2027 ( USD Million )
  2. North America SLE Market By Region, From 2022 to 2027 ( USD Million )
  3. North America Rheumatoid Arthritis Market By Region, From 2022 to 2027 ( USD Million )
  4. North America Antinuclear Antibody Testing Market By Technique, From 2022 to 2027 ( USD Million )
  5. North America Immunofluorescence Market By Region, From 2022 to 2027 ( USD Million )
  6. North America Multiplex Market By Region, From 2022 to 2027 ( USD Million )
  7. North America ELISA Market By Region, From 2022 to 2027 ( USD Million )
  8. North America Antinuclear Antibody Testing Market By Product, From 2022 to 2027 ( USD Million )
  9. North America Software Market By Region, From 2022 to 2027 ( USD Million )
  10. North America Systems Market By Region, From 2022 to 2027 ( USD Million )
  11. North America Services Market By Region, From 2022 to 2027 ( USD Million )
  12. North America Reagents & Assay Kits Market By Region, From 2022 to 2027 ( USD Million )
  13. North America Antinuclear Antibody Testing Market By End-Users, From 2022 to 2027 ( USD Million )
  14. North America Hospitals Market By Region, From 2022 to 2027 ( USD Million )
  15. North America Clinical Labs Market By Region, From 2022 to 2027 ( USD Million )
  16. United States Antinuclear Antibody Testing Market By Disease, From 2022 to 2027 ( USD Million )
  17. United States Antinuclear Antibody Testing Market By Technique, From 2022 to 2027 ( USD Million )
  18. United States Antinuclear Antibody Testing Market By Product, From 2022 to 2027 ( USD Million )
  19. United States Antinuclear Antibody Testing Market By End-Users, From 2022 to 2027 ( USD Million )
  20. Canada Antinuclear Antibody Testing Market By Disease, From 2022 to 2027 ( USD Million )
  21. Canada Antinuclear Antibody Testing Market By Technique, From 2022 to 2027 ( USD Million )
  22. Canada Antinuclear Antibody Testing Market By Product, From 2022 to 2027 ( USD Million )
  23. Canada Antinuclear Antibody Testing Market By End-Users, From 2022 to 2027 ( USD Million )

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample